The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

Size: px
Start display at page:

Download "The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals"

Transcription

1 The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey

2 The pharmaceutical industry value chain Old Organizational Paradigm Discovery Preclinical development Clinical development Approval Marketing 3-6 Years 6-7 Years ½ - 2 years 5,000-10,000 compounds 250 compounds 1 drug New Drugs 5 compounds

3 The pharmaceutical industry value chain New Organizational Paradigm Discovery Preclinical development Clinical development Approval Marketing New Drugs Source: Ed Holmes, UCSD, Presentation to Institute of Medicine 2005

4 Geography and licensing markets Biotech represents not only a technological and organizational shift, but also a shift in the geographic locus of R&D Biotech clusters are often outside the geographic footprint of traditional pharma Do licensing market operate effectively across space or does co-location matter for licensing between small biotech and large pharma? (Alcacer, Cantwell, Gittelman, 2010) Interviews with licensing execs Analysis of licensing deals What factors influence the choice of local vs. distant partnerships? (Gittelman, 2011) Serendipitous encounters in local spaces vs. scientific communities that span geographic distance

5 Does co-location matter for licensing? We know that proximity facilitates markets for upstream inputs in biotechnology (scientists, universities, venture capital)... We conceptualize licensing as downstream product markets for biotechnology firms and hypothesize that they may also be subject to similar co-location pressures. Problems in contracting for technology (Gambardella, 2008, Gans, Hsu, Stern 2008): Search costs Information asymmetries Opportunism, monitoring and coordination costs IP uncertainty Technological uncertainty Knowledge transfer If co-location reduces these frictions, we should see proximity increasing the likelihood of licensing 5

6 Interviews suggest that proximity is unimportant in licensing markets 1. Big pharma searches globally for in-licensing opportunities. Licensing a formal organizational activity Our experts know where the frontier is...we follow up on things that pique their interest. We are border blind as to where an asset comes from. There could be great scientists anywhere 2. Patent protection lower geographic bias We don t care if it s coming from the US or Brazil a good compound can come from anywhere - as long as the drug is patented in the US or Europe, where we intend to sell it 6

7 Interviews suggest that proximity is unimportant in licensing markets 3. Biotechs around the world sell globally to big pharma. If you re a small firm in India - all it takes is one BD guy sitting in Manhattan. 4. Post-license collaboration frequently discouraged by pharma Patents give detailed roadmap to technological and legal landscape Extensive due diligence before the license mitigates need for post-license collaboration Big pharma seeks to take control of the property we know how to do it [compound development], they think they do -- but they don t Virtual research teams can conduct modularized projects with little need for frequent interaction or coordination

8 Does localization matter to licensing?

9 Data 36,646 drug compounds (Pharmaprojects) Late 1980s-2006, including failed drugs Ceased (80%), Currently Active (17%), Currently Launched (3%) All licenses Type of firm/organizations developing and licensing the drug Global Pharma Biotech firms Small and mid-sized firms Universities and tech transfer Co-location - Any geographic overlap between two firms at the time of license at the city level 9

10 Selection model Colocation Model, Conditional Logit: Pr(Licenseijk) = f(co-location, city leveljk) i compound j biotech firm developing compound i k one of 25 global pharma Selection model, was drug ever licensed: Pr(Ever Licensedi) = f(compound Age, development status, co-location with any big pharma, fixed effects for therapy codes and each of the 25 Big pharma firms) 10

11 All compounds Licensed to firm j Co-location, firms i and j 0.17** (5.3) Ever licensed Co-locate, any big pharma 0.13** (14.9) Age 0.18** (120.8) Ceased -0.03** (3.7) Fully Launched -0.33** (14.7) Fixed effects, Therapy codes Obs Y Chi Sq ρ Robust Z statistics in parentheses, SE clustered on originating firm. 11

12 Does location matter? Pfizer's Research Technology Center (RTC) is located in Cambridge, MA, one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in worldleading research hospitals and academic institutions. A key element of our success is the growing, dynamic partnerships with these innovators to address the needs of patients worldwide. Pfizer website

13 Geography of knowledge flows When do firms partner locally for alliance partners, and when do they seek partners in distant locations? Conceptualize local and distant spaces as distinct opportunity sets for acquiring external technology: Distant locations Scientific networks are designed to span geographic distance. Distant partnerships reflect search of scientists for others working on similar problems: strategic, intentional search based on specific in-house R&D expertise. Local spaces Opportunities for serendipitous encounters between individuals/firms who otherwise might not know of eachother. Firms prior broadscope (general) knowledge enable them to exploit local opportunities.

14 Geography of knowledge flows The more a pharma firm has specific experience in a disease market, the more likely it will partner with a distant firm. Geographically distant partnerships will be more similar with respect to in-house R&D than local partnerships Geographically proximate partnerships correlated with general knowledge and technological variety

15 Data 1. Alliances 1038 alliances involving US biotechnology firms and 14 of the largest pharmaceutical companies, (Recombinant Capital) 2. Distance between alliance partners Minimum distance (in miles) between a biotechnology firm and the closest R&D lab of the pharma firm at the time of alliance 3. Drug portfolios of firms (Pharmaprojects) Measure in-house R&D prior to alliance Drugs by disease and by discovery platform (biotech vs. other)

16 Density Distances between alliance partners and non-alliance partners Mindist Dashed red line = distances betw. allied firms only; solid blue = distances all firms

17 Logit regressions of co-location Co-location - Alliance partners are within 100 miles of eachother Firm Disease Experience % of firm s drug portfolio in same disease as listed on alliance Firm Biotech experience % of firms drugs developed through biotech techniques Number of prior alliances by firm Need for collaboration - Co-development or Collaboration on description of alliance Stage of project: Research, Development, Preclinical, PhaseI, etc.

18 Correlation coefficient Figure 3. Correlations between alliances and in-house drugs Alliances < 100 miles and > 100 miles Alliance partners less than 100 miles Alliance partners greater than 100 miles Wyeth Eli Lilly Novartis GlaxoSmithKline Abbott Bristol-Myers Squibb Pfizer AstraZeneca Hoffmann-La Roche Sanofi-Aventis Merck & Co Schering-Plough Bayer Johnson & Johnson Firm

19 Logit models of co-location (all include fixed effects for pharma lab locations & random effects for pharma firms) Co-location=1 if firms are <100 miles Coeff Disease experience pharma firm -3.0*** 1.44 Biotech experience pharma firm 9.23*** 3.25 Disease experience biotech firm 0.60** 0.31 Biotech experience biotech firm 0.04*** 0.31 Alliance experience, Biotech firm Alliance experience, Pharma firm Early Stage -0.43* 0.2 Collaboration 0.32* 0.20 Controls for Prior Alliances, disease specified N 709 Wald Chi Square Log Likelihood SE

20 The geography of licensing Despite global search, co-location increases the probability of licensing Clusters that mix biotech firms & large pharma important nodes in markets for technology Distant and local partnerships leverage different in-house knowledge and generate different complementaries with respect to in-house R&D Distant partnerships deepen technological expertise in specific disease markets Local partnerships associated with general knowledge and technological variety speaks to the importance of proximity for serendipitous learning and exploration

21 Thank you!

22 Bio-regions most likely to out-license but - most drug compounds are never licensed Number of drugs developed, 1990s Outlicensed drugs Internationally licensed* Companies in California and Mass % 12% Global Pharma Firms (Top 14) % 10% Rest of World % 12% Total % 11% Source: Gittelman, Alcacer and Cantwell, *Internationally licensed drugs may also be domestically licensed 22

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation

Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.

More information

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation

More information

The Future of R&D Outsourcing

The Future of R&D Outsourcing OUTSOURCING The Future of R&D Outsourcing Investigating development hurdles, key challenges & strategies to optimize CRO relationships By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

TABLE OF COMMITMENTS

TABLE OF COMMITMENTS Reaching Goals On, a range of public and private partners are announcing a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by in support

More information

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com

More information

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Medical Writing Takes Off in India

Medical Writing Takes Off in India Visit http://store.centerwatch.com to learn more about State of the Clinical Trials Industry 2008 Special Article Reprint For the latest news and views on the clinical trials industry visit ClinicalTrialsToday.com

More information

New Jersey Bio-Pharmaceutical Life Sciences Landscape

New Jersey Bio-Pharmaceutical Life Sciences Landscape New Jersey Bio-Pharmaceutical Life Sciences Landscape Prepared By: John Ehret Labor Market Analyst New Jersey Department of Labor & Workforce Development Division of Labor Market & Demographic Research

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

GlycArt Biotechnology AG From Inception to trade sale and what happened after...

GlycArt Biotechnology AG From Inception to trade sale and what happened after... GlycArt Biotechnology AG From Inception to trade sale and what happened after... Dr. Joël Jean-Mairet From the Idea to Spin-off from the Swiss Federal Institute of Technology 1996 At the midst his PhD

More information

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:

More information

Life Sciences Outlook. New Jersey 2015

Life Sciences Outlook. New Jersey 2015 Life Sciences Outlook New Jersey 2015 New Jersey M&A activity in New Jersey has led to the consolidation of surplus real estate holdings and diminished head counts. However, midsized companies are helping

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies The Pharma Industry s Reputation in the Eyes of the General Public A Reputation Study with Consumers in 15 Countries RepTrak is a

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs

Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs BIO Ventures for Global Health Sharing Innovation in the Fight Against Neglected Tropical Diseases World Intellectual Property

More information

Creating Joint Value. In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century. By Ben Gomes-Casseres

Creating Joint Value. In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century. By Ben Gomes-Casseres Creating Joint Value In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century By Ben Gomes-Casseres 36 STRATEGIC ALLIANCE MAGAZINE Q3 2014 Look at any of your alliances. How do you

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Value Creation through Business Innovation in the Pharmaceutical and Medical Technology Sector

Value Creation through Business Innovation in the Pharmaceutical and Medical Technology Sector Value Creation through Business Innovation in the Pharmaceutical and Medical Technology Sector Fred Nijland Annemarie van Hoogstraten Nanning de Jong 1 Summary The Dutch market for the pharmaceutical and

More information

Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus)

Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus) STRATEGY FOCUS Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus) A strategic sales model for BI solutions in Big Pharma and Biotech Reference Code: BFTC1675

More information

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management OCTOBER 5-6, 2015 PARIS, FRANCE 6 th EDITION THE LEADING PARTNERING MEETING IN OPEN INNOVATION FOR LIFE SCIENCES CONFERENCES EXHIBITION HALL ONE-ON-ONE PARTNERING MEETINGS NETWORKING Open PRELIMINARY PROGRAM

More information

Life Sciences Outlook Switzerland. 2012

Life Sciences Outlook Switzerland. 2012 Life Sciences Switzerland. 2012 Switzerland clusters driving scientific innovation Basal (BioValley) Switzerland s largest life sciences hub and the nexus of industry leaders France, Germany and Switzerland

More information

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage

More information

Sage ERP I White Paper

Sage ERP I White Paper The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness

More information

Business Development & Licensing Journal For the Pharmaceutical Licensing Groups

Business Development & Licensing Journal For the Pharmaceutical Licensing Groups www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Consolidation in the generics sector Integrating business development Cross-cultural negotiations Self-reporting

More information

Total Compensation Measurement. Global TCM Participants. Turkey

Total Compensation Measurement. Global TCM Participants. Turkey Total Compensation Measurement 2008 Global TCM Participants Turkey Turkey 2008 TCM Participants Summary Information The table below lists key summary information on the 67 TCM participants for 2008. Measure

More information

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Ross Career Services. Health Care. Introduction. Health Care Overview

Ross Career Services. Health Care. Introduction. Health Care Overview Ross Career Services Career Path: Health Care Introduction Ross Career Services (RCS) created the Career Path series to assist students with the career search process. Each Career Path (online) handout

More information

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

OPPORTUNITY AFRICAN MARKET FOR INDIAN COMPANIES

OPPORTUNITY AFRICAN MARKET FOR INDIAN COMPANIES OPPORTUNITY AFRICAN MARKET FOR INDIAN COMPANIES G.K. Raman Regional Director PHARMEXCIL INDIAN PHARMACEUTICAL INDSTRY Manufacturers over 400 APIs (BULK DRUGS) Manufacturers over 10,000 medicaments (Formulations)

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

Patterns and predictors of suicides in the U.S. Army: An introduction to the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)

Patterns and predictors of suicides in the U.S. Army: An introduction to the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS) Patterns and predictors of suicides in the U.S. Army: An introduction to the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS) Ronald C. Kessler, Ph.D. Harvard Medical School March

More information

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

MBA in Supply Chain Management

MBA in Supply Chain Management MBA in Supply Chain Management MBA in Supply The effective supply chain has become a new organizational and operational model for the information age. Supply chain management is a business process that

More information

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME

MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways

More information

Indian Vaccines Report

Indian Vaccines Report Brochure More information from http://www.researchandmarkets.com/reports/595558/ Indian Vaccines Report Description: "Vaccine manufacturers from all over the world have been involved in a stalemate with

More information

BIOVIA: SCIENTIFIC INNOVATION IN THE AGE OF EXPERIENCE A NEW SCIENTIFIC COLLABORATIVE ENVIRONMENT

BIOVIA: SCIENTIFIC INNOVATION IN THE AGE OF EXPERIENCE A NEW SCIENTIFIC COLLABORATIVE ENVIRONMENT BIOVIA: SCIENTIFIC INNOVATION IN THE AGE OF EXPERIENCE A NEW SCIENTIFIC COLLABORATIVE ENVIRONMENT A NOTE FROM MAX BIOVIA CEO Industries needing science to create products and advance innovation require

More information

Transforming relationships Unleashing innovation

Transforming relationships Unleashing innovation Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

INCENTIVE COMPENSATION CONFERENCE

INCENTIVE COMPENSATION CONFERENCE Announcing the 2nd Annual ZS Associates INCENTIVE COMPENSATION CONFERENCE 08 September 23 24, 2008 Philadelphia, PA Incentive compensation greatly affects sales force motivation and morale. When designed

More information

Rutgers Mini-MBA : BioPharma Innovation

Rutgers Mini-MBA : BioPharma Innovation Rutgers Mini-MBA : BioPharma Innovation Ga i n t h e s k i l l s to t r a n s f o r m scientific i n n ovat i o n i n to business success www.cmd.rutgers.edu/innovation Rutgers Mini-MBA : BioPharma Innovation

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Main Conference Agenda

Main Conference Agenda Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental

More information

Global Pharmaceuticals Marketing Channel Reference EDITION

Global Pharmaceuticals Marketing Channel Reference EDITION Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry

More information

Legislative Council Secretariat FACT SHEET. Pharmaceutical industry in Denmark

Legislative Council Secretariat FACT SHEET. Pharmaceutical industry in Denmark FACT SHEET Pharmaceutical industry in Denmark 1. Introduction 1.1 The Danish pharmaceutical industry is known worldwide for providing quality drugs and medical products. In 2012, Denmark was the 16 th

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

Are market-based pharmaceutical price controls the new reality in India?

Are market-based pharmaceutical price controls the new reality in India? Are market-based pharmaceutical price controls the new reality in India? Three strategic implications for Pharma and Biotech in India Ram Subramanian Nikhil Mutyal Emma Nechamkin April 2014 www.simon-kucher.com

More information

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente?

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? 57 Congresso Nazionale SIGG Società Italiana di Gerontologia e Geriatria Dr. Marco Scatigna Direttore Medico e

More information

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd.

Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd. Roche R&D Center China (RRDCC) Media Visit to Roche in China Shanghai 30 October 2005 Andreas Tschirky, Ph.D. Head of Roche R&D Center (China) Ltd. Roche recognizes changes in China Strong economic development

More information

PROJECT PORTFOLIO MANAGEMENT WORKSHOP: Maximizing Value From Constrained Resources

PROJECT PORTFOLIO MANAGEMENT WORKSHOP: Maximizing Value From Constrained Resources PROJECT PORTFOLIO MANAGEMENT WORKSHOP: Maximizing Value From Constrained Resources WHO SHOULD ATTEND Participants involved in Project Management, Portfolio Management, Strategic & Business Planning, Product

More information

Emerging Business Models in the Pharmaceutical Industries. Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players

Emerging Business Models in the Pharmaceutical Industries. Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players Emerging Business Models in the Pharmaceutical Industries Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players JSB Intelligence Kildare House, 102-104 Sheen Road Richmond, TW9

More information

European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo

European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo 1 Overview 1. Venture Valuation 2. Trends in the EU Biotech & Pharma 3. Overview European Biotechs / Clusters 2 Valuation Valuation Mission Independent

More information

Life Sciences Outlook. San Diego 2015

Life Sciences Outlook. San Diego 2015 Life Sciences Outlook San Diego 2015 San Diego San Diego saw $43.8 billion in M&A transactions from 2011 through 2014. Large pharmaceutical companies are purchasing biotech firms to fill their R&D pipelines,

More information

1) SCOPE OF THE PROGRAM

1) SCOPE OF THE PROGRAM CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

More information

Carol Lefebvre Senior Information Specialist UK Cochrane Centre National Institute for Health Research Oxford, UK

Carol Lefebvre Senior Information Specialist UK Cochrane Centre National Institute for Health Research Oxford, UK Clinical trials registers and clinical trials results registers: their contribution as health information sources to evidence-based healthcare decision-making Carol Lefebvre Senior Information Specialist

More information

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Creative financing: Private equity in life sciences

Creative financing: Private equity in life sciences : Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access

More information

Acucela Inc. IR Meeting

Acucela Inc. IR Meeting Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening

More information

Everest Group s PEAK Matrix for Life Sciences ITO Service Providers

Everest Group s PEAK Matrix for Life Sciences ITO Service Providers Everest Group s PEAK Matrix for Life Sciences ITO Service Providers Focus on Wipro July 2014 Copyright 2014 Everest Global, Inc. This document has been licensed for exclusive use and distribution by Wipro

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge

More information

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors

More information

Global Peptide Therapeutics Market 2014-2018

Global Peptide Therapeutics Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences

More information

Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013

Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013 Brochure More information from http://www.researchandmarkets.com/reports/2599260/ Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013 Description: Synopsis This

More information

Profile of Biomedical Research and Biotechnology Commercialization. Philadelphia Wilmington Atlantic City Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. Philadelphia Wilmington Atlantic City Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization Philadelphia Wilmington Atlantic City Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Metropolitan

More information

Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies

Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies, MBS Molly Schmid, Ph.D. Table of Contents Introduction.2 Methodology.. 2 Results

More information

When treating a disease is bad business: orphan and neglected diseases

When treating a disease is bad business: orphan and neglected diseases When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

Problems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability

Problems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability University of Pennsylvania ScholarlyCommons Master of Science in Organizational Dynamics Theses Organizational Dynamics Programs 5-4-2010 Problems Facing the Pharmaceutical Industry and Approaches to Ensure

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 Introduction OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 In 2007, Attorney General Wasden filed lawsuits against 33 pharmaceutical companies for

More information

Campbell Alliance. Press Kit Materials

Campbell Alliance. Press Kit Materials Campbell Alliance Press Kit Materials Raleigh, N.C. Parsippany, N.J. Woodland Hills, Calif. South San Francisco Chicago New York City TABLE OF CONTENTS Document Page # About Campbell Alliance 3 Company

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many

More information

INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS

INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS I. INTRODUCTION The International Pharmaceutical Privacy Consortium (IPPC)

More information

CorMedix, Inc. (CRMD) - Product Pipeline Analysis

CorMedix, Inc. (CRMD) - Product Pipeline Analysis Brochure More information from http://www.researchandmarkets.com/reports/1595808/ Description: Summary CorMedix, Inc. (CorMedix) is a pharmaceutical company, based in the US. It develops and seeks to commercialize

More information

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system

More information

CAN-SPAM Act Rulemaking, Project No. R411008

CAN-SPAM Act Rulemaking, Project No. R411008 1301 K Street NW Suite 900 East Tower Washington DC 20005-3317 Telephone 202 230 5619 Facsimile 202 230 5300 June 27, 2005 By Hand Federal Trade Commission Office of the Secretary, Room H-159 600 Pennsylvania

More information

Digital Leaders Deal With a Range of Organizational Challenges

Digital Leaders Deal With a Range of Organizational Challenges May 22, 2014 OVERCOMING OBSTACLES TO DIGITAL TRANSFORMATION SUCCESS IN THE PHARMACEUTICAL INDUSTRY Digital Leaders Deal With a Range of Organizational Challenges by Tim van Tongeren with Dennis van Rooij

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

Lead the Future of Pharmaceutical Science

Lead the Future of Pharmaceutical Science MYLAN SCHOOL OF PHARMACY AND THE GRADUATE SCHOOL OF PHARMACEUTICAL SCIENCES Lead the Future of Pharmaceutical Science GRADUATE SCHOOL OF PHARMACEUTICAL SCIENCES: A NATIONAL LEADER ABOUT DUQUESNE UNIVERSITY

More information

Report: The Relation of Biotech and Big Pharma: Feeding the Pipeline

Report: The Relation of Biotech and Big Pharma: Feeding the Pipeline Report: The Relation of Biotech and Big Pharma: Feeding the Pipeline Blockbuster pharmaceuticals are on the verge of patent expirations while late-stage product pipelines are barren, thus shaking the foundations

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012 The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered

More information

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics

Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics Driving Innovation in Licensing Through Competitive Intelligence and Big Data Analytics John D Antonio Practice Leader, Licensing & Competitive Intelligence About Paragon We help increase asset value from

More information